August 9, 2022
A first-of-its-kind study on treating posttraumatic headache (PTH), for which no current treatments are available, is underway and led by Research Manager Annabel Lee Raboy, M.S.W., an HJF employee at the Uniformed Services University’s Center for Neuroscience and Regenerative Medicine. PTH is a secondary headache disorder that develops approximately seven days after a head and/or neck injury and affects about half of those who experience mild traumatic brain injuries.
The multi-site clinical trial, “Treatment of Acute Posttraumatic Headache with a GCRP Receptor mAb in Military Service Members and Civilians with Mild Traumatic Brain Injury,” will test the safety and effectiveness of a migraine medicine, erenumab.
“This study aims to help millions of people affected by posttraumatic headache. It is a focus that our study team is invested in both professionally and personally; as we are deeply connected to our service members and veterans. If erenumab proves to be an effective intervention, it would be among the first evidence-based methods to prevent and treat these complex and debilitating headaches, and make a big impact on the quality of life for those experiencing them,” said Ms. Raboy.
By the end of 2026, the clinical trial aims to have 404 participants enrolled, which is currently open to the Naval Medical Center Camp Lejeune, Brooke Army Medical Center, and Womack Army Medical Center. Later this year, William Beaumont Army Medical Center will become a fourth site for participant enrollment.